RP-182

RP-182 is a synthetic, 10-mer amphipathic peptide analog of host defense peptides designed to selectively target the mannose receptor (CD206) expressed on M2-like tumor-associated macrophages. By binding to CD206, RP-182 induces a conformational change that activates endocytosis, phagocytosis, autophagy, and apoptosis in these immunosuppressive macrophages, leading to their depletion and repolarization toward a pro-inflammatory, antitumor M1-like phenotype. This macrophage reprogramming is associated with improved innate and adaptive antitumor immune responses, increased tumor cell phagocytosis, and enhanced antitumor activity in preclinical cancer models, including as a combination partner with chemotherapy or immune checkpoint inhibitors. Preclinical studies have also explored its activity in non-cancer inflammatory diseases such as lung fibrosis. RP-182 was developed through in silico homology screening to mimic conserved motifs in host defense peptides.[1][2][5][9]

Other names

RP peptides (Oncology)Riptide oncology peptidesRiptide drug candidates